Dr. Reddy's Laboratories announces the launch of Vigabatrin Tablets, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril® (vigabatrin) Tablets, USP, approved by the U.S. Food and Drug Administration (USFDA).

"We are pleased that this product has been designated as a Competitive Generic Therapy (CGT) by the FDA," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories. "With a CGT designation, we have 180-day CGT exclusivity to market this product."

The Sabril® brand and generic had U.S. sales of approximately $141 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.

Dr. Reddy's Vigabatrin Tablets, USP are available in 500 mg tablets in a bottle count size of 100.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4428.6 as compared to the previous close of Rs. 4598.65. The total number of shares traded during the day was 82583 in over 8955 trades.

The stock hit an intraday high of Rs. 4577.2 and intraday low of 4395. The net turnover during the day was Rs. 366267295.

Source : Equity Bulls

Keywords